Sustainability & Climate

Engineered by NIST to last centuries, America's official time capsule will be sealed in 2026. What story of us will it tell future generations?

Nautilus Biotechnology cuts losses and preps its Voyager platform for a late 2026 launch, targeting the next frontier in neurodegenerative disease research.

Spectral Medical shifts its FDA submission for a breakthrough sepsis device, a strategic move that could strengthen its case but delays a potential lifeline.

Romania's new 1,500km quantum network, powered by IonQ, marks a major step in Europe's race to secure critical data against future cyber threats.

A new partnership aims to capitalize on surging defense spending and supply chain shifts, signaling a new era for specialized private equity investing.

After a massive divestiture, Vistance Networks reports soaring growth, zero debt, and plans a huge special cash distribution to its shareholders.

With a key FDA decision looming and pivotal data on a second therapy imminent, Viridian is poised to reshape the multi-billion dollar Thyroid Eye Disease market.

As colorectal cancer rates rise in younger adults, advocates demand provinces lower the screening age. But will policymakers act on the growing evidence?

After a strong 2025, Viatris unveils a plan for $650M in savings, a 10% workforce cut, and a focus on six new drugs to fuel future innovation.

The plant-based giant adds four new flavors to its Immerse drink, a strategic pivot into the booming functional beverage market amid struggles in meat.

With its strategic pivot to high-growth Med Tech paying off, all eyes are on AngioDynamics' CEO presentation at the upcoming Leerink healthcare conference.

Houston showroom recognized at KBIS 2026 for its immersive, hands-on approach, setting a new standard for the home remodeling customer experience.

The ad-tech giant posted record revenue for 2025, but a weaker-than-expected forecast for early 2026 sent its stock tumbling. What's next?

MiMedx reports record 2025 sales and a $100M buyback, but faces a major challenge from new Medicare reimbursement rules set to disrupt the wound care market.

The diagnostics firm beat Q4 estimates with a 705% profit jump, driven by its Decipher and Afirma tests, and plans to launch two new products in 2026.

FTAI Aviation reports a massive profit turnaround and raises its dividend, signaling confidence. But a pivot to power generation may be the real story.

With stellar clinical data and a full war chest, Terns is hitting the road to convince investors its leukemia drug, TERN-701, is a true disruptor.

Labour unions and students decry the Ford government's plan to shift OSAP from grants to loans, warning of crippling debt and reduced access to education.

Global home care provider Dovida acquires U.S. franchise A Place At Home, bringing its international, person-centered model to an aging America.

A new oral drug shows remarkable success in healing stubborn herpes lesions in people with HIV, offering a much-needed breakthrough for a vulnerable population.